BMJ Open

OBJECTIVE: To evaluate the effect of air pollution, from oocyte retrieval to embryo transfer, on the results of in vitro fertilisation (IVF) in terms of clinical pregnancy rates, at two fertility centres, from 2013 to 2019. DESIGN: Exploratory retrospective cohort study. SETTING: This retrospective cohort study was performed in the Reproductive Biology Department of Bordeaux University Hospital localised in Bordeaux, France and the Jean Villar Fertility Center localised in Bruges, France. PARTICIPANTS: This study included 10 763 IVF attempts occurring between January 2013 and December 2019, 2194 of which resulted in a clinical pregnancy. PRIMARY AND SECONDARY OUTCOME MEASURES: The outcome of the IVF attempt was recorded as the presence or absence of a clinical pregnancy; exposure to air pollution was assessed by calculating the cumulative exposure of suspended particulate matter, fine particulate matter, black carbon, nitrogen dioxide and ozone (O(3)), over the period from oocyte retrieval to embryo transfer, together with secondary exposure due to the presence of the biomass boiler room, which was installed in 2016, close to the Bordeaux University Hospital laboratory. The association between air pollution and IVF outcome was evaluated by a random-effects logistic regression analysis. RESULTS: We found negative associations between cumulative O(3) exposure and clinical pregnancy rate (OR=0.92, 95% CI = (0.86 to 0.98)), and between biomass boiler room exposure and clinical pregnancy rate (OR=0.75, 95% CI = (0.61 to 0.91)), after adjustment for potential confounders. CONCLUSION: Air pollution could have a negative effect on assisted reproductive technology results and therefore precautions should be taken to minimise the impact of outdoor air on embryo culture

Innovative methods of transgenesis in rats : application to model Parkinson's disease

Les avancées récentes dans la technique de transgénèse utilisant l’approche AAV ont permis de générer de nouveaux modèles animaux. Depuis quelques années, le développement des modèles de la maladie de Parkinson (MP) a amélioré la compréhension des mécanismes physiopathologiques de ce trouble dégénératif. Cependant, aucun modèle mammifère ne reproduit à ce jour la neurodégénérescence liée à l’âge associée à la pathologie synucléine et la symptomatologie motrice et non motrice. L’objectif de mon travail de thèse fut de développer de nouvelles stratégies de transgénèse chez le rat en utilisant ces vecteurs viraux pour la modélisation de la MP. Le challenge est de parvenir à une infection virale la plus précoce possible afin de transduire un maximum de neurones dopaminergiques. Pour cela, différentes voies d’approche ont été testées pour améliorer le processus de transgénèse : 1) l’injection de vecteurs viraux dans le rete testis de jeunes mâles pour transduire les cellules de la lignée germinale, 2) l’injection dans les embryons pré-implantatoires, 3) l’injection in utero intracérébroventriculaire et enfin 4) l’injection intracardiaque au premier jour de vie des animaux. Parmi elles, les injections in utero et intracardiaques ont permis d’aboutir à une transduction importante d’un grand nombre de structures cérébrales avec un tropisme neuronal. Ces techniques ouvrent la voie à la génération de nouveaux modèles animaux de maladies à composante génétique et à la thérapie génique.Recent advances in the transgenesis technique using the AAV approach have led to the generation of new animal models. In recent years, the development of models of Parkinson's disease (PD) has improved understanding of the pathophysiological mechanisms of this degenerative pathology. However, no mammalian model recapitulates the required age-dependant parkinsonian degeneration, the α-synuclein inclusion pathology and motor and non-motor symptoms. The objective of my Ph.D work was to develop new transgenesis strategies in rats using these viral vectors for modeling PD. The challenge is to achieve a viral infection as early as possible in order to transduce as many dopaminergic neurons as possible. To this end, different strategies have been tested to improve transgenesis efficacy : i) injection in rete testis in young male to transduce germinal cells, ii) injection into early stage embryos, iii) in utero intracerebroventricular injection and iv) intracardiac injection in one day-old animals. Among them, in utero and intracardiac injections led to neuronal transgene expression in most regions of the brain. These techniques pave the way for the generation of new animal models of genetic diseases and offer unique opportunities for gene therapy

Innovative methods of transgenesis in rats : application to model Parkinson's disease

Les avancées récentes dans la technique de transgénèse utilisant l’approche AAV ont permis de générer de nouveaux modèles animaux. Depuis quelques années, le développement des modèles de la maladie de Parkinson (MP) a amélioré la compréhension des mécanismes physiopathologiques de ce trouble dégénératif. Cependant, aucun modèle mammifère ne reproduit à ce jour la neurodégénérescence liée à l’âge associée à la pathologie synucléine et la symptomatologie motrice et non motrice. L’objectif de mon travail de thèse fut de développer de nouvelles stratégies de transgénèse chez le rat en utilisant ces vecteurs viraux pour la modélisation de la MP. Le challenge est de parvenir à une infection virale la plus précoce possible afin de transduire un maximum de neurones dopaminergiques. Pour cela, différentes voies d’approche ont été testées pour améliorer le processus de transgénèse : 1) l’injection de vecteurs viraux dans le rete testis de jeunes mâles pour transduire les cellules de la lignée germinale, 2) l’injection dans les embryons pré-implantatoires, 3) l’injection in utero intracérébroventriculaire et enfin 4) l’injection intracardiaque au premier jour de vie des animaux. Parmi elles, les injections in utero et intracardiaques ont permis d’aboutir à une transduction importante d’un grand nombre de structures cérébrales avec un tropisme neuronal. Ces techniques ouvrent la voie à la génération de nouveaux modèles animaux de maladies à composante génétique et à la thérapie génique.Recent advances in the transgenesis technique using the AAV approach have led to the generation of new animal models. In recent years, the development of models of Parkinson's disease (PD) has improved understanding of the pathophysiological mechanisms of this degenerative pathology. However, no mammalian model recapitulates the required age-dependant parkinsonian degeneration, the α-synuclein inclusion pathology and motor and non-motor symptoms. The objective of my Ph.D work was to develop new transgenesis strategies in rats using these viral vectors for modeling PD. The challenge is to achieve a viral infection as early as possible in order to transduce as many dopaminergic neurons as possible. To this end, different strategies have been tested to improve transgenesis efficacy : i) injection in rete testis in young male to transduce germinal cells, ii) injection into early stage embryos, iii) in utero intracerebroventricular injection and iv) intracardiac injection in one day-old animals. Among them, in utero and intracardiac injections led to neuronal transgene expression in most regions of the brain. These techniques pave the way for the generation of new animal models of genetic diseases and offer unique opportunities for gene therapy

Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats

International audienceAbstractRecombinant adeno-associated virus serotype 9 (rAAV2/9) and pseudotype rhesus-10 (rAAV2/rh10) are used for gene delivery, especially into the central nervous system. Both serotypes cross the blood-brain barrier and mediate stable long-term transduction in dividing and nondividing cells. Among possible routes of administration, intracardiac injection holds the potential for widespread vector diffusion associated with a relatively simple approach. In this study adopting the intracardiac route, we compare the cell-specific tropism and transfection efficacy of a panel of engineered rAAV2/9 and rAAV2/rh10 vectors encoding the enhanced green fluorescent protein. We observed transduction in the brain and peripherally, with a predominant neuronal tropism while the various serotypes achieved different expression patterns

Sperm aneuploidy and DNA fragmentation in unexplained recurrent pregnancy loss: a multicenter case-control study

International audienceBackground: Recurrent pregnancy loss (RPL) is defined as the loss of at least three pregnancies in the first trimester. Although the most common cause is embryo aneuploidy, and despite female checkup and couple karyotyping, in about 50% of cases RPL remain unexplained. Male implication has little been investigated and results are discordant. In this context, we conducted a multi-center prospective case-control study to investigate male gamete implication in unexplained RPL. Methods: A total of 33 cases and 27 controls were included from three university hospitals. We investigated environmental and family factors with a detailed questionnaire and andrological examination, sperm characteristics, sperm DNA/chromatin status using the sperm chromatin structure assay (SCSA) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and sperm aneuploidy using fluorescence in situ hybridization (FISH). The Mann-Whitney test and the Wilcoxon or Fisher exact tests were used. A non-parametric Spearman correlation was performed in order to analyze the relationship between various sperm parameters and FISH and sperm DNA fragmentation results. Results: We found significant differences between cases and controls in time to conceive, body mass index (BMI), family history of infertility and living environment. In cases, total sperm motility and the percentage of morphologically normal spermatozoa were significantly decreased. No difference was found between cases and controls in sperm DNA fragmentation or chromatin integrity. In cases, spermatozoa with aneuploidy, hyperhaploidy and chromosome 18 disomy were significantly increased. Conclusions: This prospective case-control study is one of the largest to examine environmental factors, sperm characteristics, sperm DNA fragmentation and chromatin, and chromosome anomalies in spermatozoa in relation to unexplained recurrent pregnancy loss. The originality of our study lies in the comprehensive andrological examination and search for risk factors and fertility history. Further studies are needed to confirm the links between unexplained RPL and a male family history of infertility or miscarriages. The increased sperm aneuploidy observed in unexplained RPL supports a male etiology. These data pave the way for further studies to demonstrate the value of preimplantation genetic screening in men with increased sperm aneuploidy whose partners experience unexplained RPL